Insider · CIK 0001588389
Mansoor Raza Mirza
Files at KPTI (Karyopharm Therapeutics Inc.), SERA (SERA PROGNOSTICS, INC.), ACRV (Acrivon Therapeutics, Inc.). First filing Nov 12, 2024, latest Dec 5, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SERA: SERA PROGNOSTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | SERA PROGNOSTICS, INC. | $891 292 shares | -1% | +107% from low-65% from high | |
| 30Weak | SERA PROGNOSTICS, INC. | $672 221 shares | -0% | +107% from low-65% from high | |
| 23Weak | SERA PROGNOSTICS, INC. | $717 227 shares | -0% | +119% from low-63% from high | |
| 30Weak | SERA PROGNOSTICS, INC. | $744 222 shares | -0% | +124% from low-62% from high | |
| 30Weak | SERA PROGNOSTICS, INC. | $563 225 shares | -0% | +64% from low-72% from high | |
| 15Weak | SERAsell SERA PROGNOSTICS, INC. | $552 234 shares | -0% | +62% from low-72% from high | |
| 30Weak | SERA PROGNOSTICS, INC. | $169 107 shares | -0% | 0% from low-82% from high | |
| 30Weak | SERA PROGNOSTICS, INC. | $259 106 shares | -0% | 0% from low-76% from high | |
| 15Weak | SERAsell SERA PROGNOSTICS, INC. | $358 107 shares | -0% | +8% from low-61% from high | |
| 30Weak | SERA PROGNOSTICS, INC. | $662 93 shares | -1% | - | |
| 30Weak | SERA PROGNOSTICS, INC. | $695 95 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +174,068 | $0.00 | $0 | 174,068 | Mar 3, 2026 |
| Dec 5, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -292 | $3.05 | $891 | 57,740 | Dec 5, 2025 |
| Nov 5, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -221 | $3.04 | $672 | 58,032 | Nov 6, 2025 |
| Oct 6, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -227 | $3.16 | $717 | 58,253 | Oct 6, 2025 |
| Oct 1, 2025 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Oct 3, 2025 |
| Sep 5, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -222 | $3.35 | $744 | 58,480 | Sep 5, 2025 |
| Aug 5, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -225 | $2.50 | $563 | 58,702 | Aug 5, 2025 |
| Jul 7, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -234 | $2.36 | $552 | 58,927 | Jul 8, 2025 |
| Jun 5, 2025 | SERA SERA PROGNOSTICS, INC. | AGrant or award Class A Common Stock | +15,596 | $0.00 | $0 | 59,268 | Jun 6, 2025 |
| Jun 6, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -107 | $1.58 | $169 | 59,161 | Jun 6, 2025 |
| Jun 5, 2025 | SERA SERA PROGNOSTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 6, 2025 |
| May 28, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Nonstatutory Stock Option (right to buy)derivative | +4,600 | $0.00 | $0 | 4,600 | May 29, 2025 |
| May 8, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -106 | $2.44 | $259 | 43,672 | May 9, 2025 |
| Apr 7, 2025 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -107 | $3.35 | $358 | 43,778 | Apr 8, 2025 |
| Dec 6, 2024 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -93 | $7.12 | $662 | 6,636 | Dec 9, 2024 |
| Nov 11, 2024 | SERA SERA PROGNOSTICS, INC. | SOpen-market sale Class A Common Stock | -95 | $7.32 | $695 | 6,729 | Nov 12, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.